These results suggest the existence of a mechanism for reutilization of the biliary products of vitamin D3.
INTRODUCTION
To act physiologically vitamin D must be metabolized to 25-hydroxyvitamin D3 in the liver and then to 1,25-dihydroxyvitamin D3 in the kidney (1) . The peripheral metabolism of vitamin D homologues, however has received little attention. Evidence has been presented to show that at least one vitamin D3 homologue, 1,25-dihydroxyvitamin D3, is metabolized in several ways (2) (3) (4) . Furthermore, there is strong evidence to suggest that the biliary route of excretion is an important pathway in the metabolism of several vitamin D3 compounds (5) (6) (7) (8) (9) . We have recently shown that products of 1,25-dihydroxyvitamin D3 (5) and 24,25-dihydroxyvitamin D3 (6) are excreted in bile as polar compounds, reabsorbed in the intestine, and re-excreted in bile. It is likely that one of the metabolites present in bile is a glucosiduronate of 1,25-dihydroxyvitamin D3 (5) . Earlier, Bell and Kodicek (7) demonstrated that vitamin D3 3,8-glucosiduronate was probably excreted in rat bile. Therefore, glucuronides of at least two vitamin D3 homologues are known to exist in vivo.
There are several unresolved questions concerning the metabolism of vitamin D homologue glucosiduronates: Do these compounds have biological activity? If so, are they active per se or do they need to be hydrolyzed to the parent vitamin D3 homologue? Is it possible that the biliary excretion and subsequent reabsorption of these compounds in the intestine is a mechanism whereby the organism can conserve vitamin D3 and thus prevent rapid depletion of this vitamin? To 400 ,ul of blood was drawn to measure serum calcium or phosphorus levels. 24 h later, the rats were decapitated and their blood was collected. The first 10 cm of the duodenum was removed. Duodenal intestinal calcium transport was measured by the everted gut sac technique of Martin and DeLuca (10) .
Duodenal organ culture. This was performed as described by Corradino (11) . To detect the presence of 8-glucuronidase in the system, [3H]tetrahydroaldosterone 3,8-glucosiduronate (concentration 10,845 dpm/ml in water) was added to the medium. The absence offree tetrahydroaldosterone was detected by DEAE chromatography. Salts in the culture medium were removed by applying the solution to a 1 x 25-cm Amberlite XAD-2 (Rohm & Haas Co., Philadelphia, Pa.) column; the water soluble salts were eluted with 150 ml of water. Organic materials were subsequently eluted with 150 ml of methanol. 10-ml fractions were collected; radioactivity was measured in aliquots taken from the eluate. The methanolic fractions that had detectable radioactivity were collected, pooled, and dried on a flash evaporator. The resulting oily residue was subjected to DEAE batch elution chromatography. DEAEcellulose (10 g) was equilibrated in methanol. The residue was resuspended in methanol and applied to the gel. The gel was eluted with methanol (100 ml) and later with 25% acetic acid in methanol (100 ml). The solvents were evaporated and the radioactivity was determined.
Serum calcium and inorganic phosphorus measurements. Serum calcium or phosphorus were measured after appropriate doses of either vitamin D3, vitamin D3 3,8-glucosiduronate, ' Abbreviations used in this paper: CaBP, calcium-binding protein; HPLC, high performance liquid chromatography;M+, parent molecular ion; m/e, mass/energy ratio. or vehicle by intravenous, intraperitoneal, or oral routes. Serum calcium was determined with an atomic absorption spectrometer (Perkin-Elmer Corp., Instrument Div., Norwalk, Conn.; model 303) using 0.1% LaCl3 as diluent. Serum inorganic phosphorus was determined by a colorimetric assay (12) .
25-Hydroxyvitamin D assay. The serum 25-hydroxyvitamin D levels were measured as previously described (13) .
Statistical analysis. The statistical analysis were performed as described by Bancroft (14) .
Synthesis of methyl (9, (16) in dry benzene (25-30 ml) was added at the same rate as the rate of distillation. After addition of about half of the bromide solution, an additional 1 g (3.63 mmol) of dried silver carbonate was added to the reaction mixture. The reaction was followed by thin-layer chromatography; when the reaction was complete, the reaction flask was cooled, the silver salt was filtered and washed with an additional quantity (2 x 15 ml) of dry benzene. The filtrate and the washings were combined, dried over anhydrous sodium sulfate and the solvent was removed on a rotary evaporator. The residual oil was chromatographed on a silica gel 60 H column (Merck AG, Darmstadt, West Germany) with 10% ether-hexane as the eluting solvent. The unreacted bromide was separated from the product, and the latter was recrystallized from hot ethanol. The yield was 85-90%. The melting point of the product was 72°-73°C; UV spectrometry showed X maximum at 265 nm and X minimum at 228 nm. The mass spectrum contains a peak for parent molecular ion at mass/energy (m/e) 700 (M+) and peaks at 383 (M-pyronium ion)', 366 (M-pyronium ion-H20)'. Peaks at m/e 317 (pyronium ion)', 257 (C,,H1307)+, 155 (C7H704)+, 95 (C5H302)+, 60 (methyl formate or acetic acid)+ establish the presence of triacetylated sugar moiety (Fig. 1) .
Preparation of vitamin D333-glucosiduronate (sodium 9,10-secocholesta-5,7,10[ 1 9]trien-3-yl-,3D-glucopyranosiduronate) (17) . To a solution of 100 mg (0.143 mmol) of methyl-(9,10-secocholesta-5,7,10[19]-trien-3,3-yl-2',3',4'-tri-O-acetyl-,8-Dglucopyranosid)uronate in 10 ml of 1:1 mixture of anhydrous methanol and dichloromethane, 1 ml of 0.1 N sodium hydroxide in anhydrous methanol was added. After 2-h stirring at room temperature 20 ml of distilled tetrahydrofuran was added. After this, aqueous sodium hydroxide (10 ml, 1 N) was added over a period of 10 JL.6 -was dissolved by the addition of 20 ml of methanol. The water was removed from the flask and the mixture was allowed to react for an additional 30-45 min. The solvent was concentrated until all the organic solvent was removed and an oily semi-solid reappeared in the reaction mixture. The semi-solid was washed several times with water (10 ml). The oily material was dissolved in methanol and a foamy solid was obtained on evaporation of the solvent. Purification ofvitamin D33-glucosiduronate. The foamy solid obtained in the above experiment was further purified on an HPLC system using acetonitrile-water (1:1.86) as the starting solvent. A linear gradient was developed over a period of 15 min at a flow rate of 2 ml/min. The final eluent was 100% acetonitrile. The HPLC profile of the title compound is shown in Fig. 2 . The ultraviolet spectrum of vitamin D3 glucosiduronate (Fig. 3) exhibited a curve expected of the vitamin D chromophore with an absorbance maximum at 265 nm and an absorbance minimum at 228 nm. (19) , it appears that the hydrolysis does not take place to a great extent in bile as only small quantities of free sterol were found in rat bile (5). However, endogenous intestinal cell glucuronidases and/or bacterial glucuronidases may play an important, though unproved, role in the formation ofthe free sterol.
,B-Glucuronidase in other tissues may also play a significant role. It is unlikely that the intact conjugate is biologically active because it fails to increase CaBP synthesis in an embryonal duodenal system at doses several orders of magnitude higher than the dose of vitamin D3 necessary to elicit such a response. A model radiolabeled conjugate, tetrahydroaldosterone 3,3-glucosiduronate, is not hydrolyzed and hence, it is unlikely that vitamin Ds 33,8-glucosiduronate undergoes hydrolysis in this organ culture system. These data would suggest that the intact sterol conjugate is inactive. Further evidence supporting the necessity of hydrolysis of the conjugate to the free sterol is the appearance of 25-hydroxyvitamin D in the sertum after a dose of the conjugate. The increment in serum 25-hydroxyvitamin D3 levels is in accordance with the observed activity of the conjugate relative to vitamin D3. Thus, it is likely that the conjugate is biologically inactive unless it undergoes hydrolysis to release the active aglycon, vitamin D3, which is in turn metabolized to 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3.
Our data lead us to believe that the conjugation and excretion of vitamin D3 3,3-glucosiduronate in bile may not merely be an excretory process. The conjugate may be reutilized, most likely by hydrolysis to the free sterol. It is likely, though unproved at present, that other glucosiduronates of vitamin D3 homologues may also be reutilized in this manner. In any event, were defects in the hydrolysis and reutilization of the conjugates of vitamin D3 homologues to occur in organs such as the intestine, it is possible that less vitamin D3 would be available for utilization by the organism. We speculate that such a situation could arise in diseases associated with a decreased intestinal transit time; in this situation there may be inadequate time available for /-glucuronidases to hydrolyze substrate. Alternatively, there may be a decrease in the amount of 8-glucuronidase present. It is possible that alterations in this process could contribute, in part, to the vitamin D deficiency seen in hepatic and intestinal disease.
